Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 74.03

-0.6%

Nov 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe Wesley who wrote (2026)	6/10/1998 2:34:00 AM
From: Miljenko Zuanic	Read Replies (1) of 4676

Amateur and others: WS do not have any respect toward ISIP and many platform and development stage bts. It is not uncertainty about prosperity, it is total ignorance. This deal, regardless that we do not know financial condition and actually HCV target (DoPont Merck have collaboration with Genelabs for DNA binding small molecules valued at +20 mm) , is nice confirmation of the Isis combinatorial chemistry capability. Merck is known as company which is rarely licensing other companies small molecule libraries or combinatorial chemistry capability. So, why Merck show interest in Isis small molecules? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next